Kuria Therapeutics Closes Initial Fundraising Round to Develop Novel Nrf2 Activator

LITTLE ROCK, Ark.--(BUSINESS WIRE)--Kuria Therapeutics, a pharmaceutical company developing novel ophthalmic and dermal therapeutics, announced that it has successfully closed its first fundraising round. The offering was met with significant enthusiasm and allowed the company to establish a base of experienced investment partners. Kuria’s lead product candidate is a topical ophthalmic formulation of SCO-116, a novel Nrf2 activator being developed under a license from SCOHIA PHARMA (https://www